Home › Trials › NCT07153172
Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 and up

Safety follow-up after INV-347 dosing in INV-CL-108

Official title: Safety Follow-up Study of Participants Previously Dosed With INV-347 in the First-in-Human Study INV-CL-108

Run by Novo Nordisk A/S · NCT07153172 · Data updated 2026-11-12

This follow-up checks the safety and blood levels of INV-347 in adults who previously received INV-347 in INV-CL-108.

More Obesity trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment91 (estimated)
SponsorNovo Nordisk A/S
Industry-sponsored
Locations1 site (Québec)
StatusRecruiting
StartedAugust 6, 2025
Main results expectedSeptember 15, 2027
Study endsSeptember 15, 2027
Registry record updatedMarch 6, 2026
Trial IDNCT07153172 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (age 18+) who were previously dosed with INV-347 in INV-CL-108 and who have a measurable INV-347 plasma level above 0.5 ng/mL at enrolment are eligible.

Probably not a fit

People who did not receive INV-347 in INV-CL-108 or who have no measurable INV-347 in their blood are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study follows adults who were previously dosed with INV-347 in INV-CL-108 to monitor safety and measure plasma concentrations over time. No additional study drug will be given; participants will attend scheduled visits through visit 21 for blood sampling and safety assessments. To enroll, participants must be 18 or older and have a measurable INV-347 plasma concentration above the lower limit of quantification (0.5 ng/mL). The study is sponsored by Novo Nordisk and is being conducted at Syneos Health Clinique in Québec.

Why it matters

Potential benefit: If successful, the follow-up could improve understanding of how long INV-347 persists in the body and confirm its longer-term safety after dosing.

How similar studies have gone: Post-dosing safety and pharmacokinetic follow-ups are common and have previously informed dosing and monitoring decisions for other drugs, though INV-347-specific long-term data remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
2. Male or female (sex at birth).
3. Age 18 years or above at the time of signing the informed consent.
4. Previously dosed with INV-347 in study INV-CL-108 and with measurable INV-347 concentration in plasma at enrolment \[above lower limit of qualification (LLOQ) of 0.5 nanogram per milliliter (ng/mL)\].

Exclusion Criteria:

The study has no exclusion criteria.

Where it's running

  • Syneos Health Clinique
    Québec, Canada     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Obesity 1426Novo Nordisk A/S 70
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.